Shares of Godavari Biorefineries were locked in the 5% upper circuit on Wednesday after the company announced it had received a patent from China for a key anti-cancer compound.
The patent, granted by the China National Intellectual Property Administration (CNIPA), covers 5-Hydroxy-1,4-Naphthalenedione — a novel compound that has shown strong inhibitory effects on cancer and cancer stem cells in lab studies. According to the company, this compound has demonstrated encouraging results against multiple types of cancer, including breast and prostate cancer.
Management expressed confidence that this development not only strengthens their intellectual property portfolio, but also opens up new opportunities in the global oncology space.
The stock surged on the back of this positive update, with investors betting on the long-term potential of the breakthrough.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
